Unstoppable Takeda to acquire Ariad Pharmaceuticals for $5.2bn (73% premium)

Japan-based Takeda Pharmaceutical today announced it has acquired US-based Ariad Pharmaceuticals for $5.2bn, that is $24 per share, which represents a 73% premium to the stock’s closing share price (NASDAQ) on Friday. The acquisition expands Takeda’s oncology portfolio with two important treatments: Brigatinib, targeting a rare lung cancer (NSCLC) and Iclusig, targeting a particular subset of leukemia(CML). The two Aried’s products join Takeda’s oncology treatments: Adcetris, Ninlarotm and Velcade. Takeda will pay Ariad $1.2bn in cash and $4.0bn by ad hoc debt facilities. (Source Takeda)